Mohammed Reza, MD
Infectious Disease · Jacksonville, FLNPI 1174753933
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Viiv Healthcare Company at 43.1% of the total. Reporting peaked in 2022 at $20,217 and has fallen 57.5% since, to $8,600 in 2025. Among infectious disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 636 payments — averaging $96.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$26K
- Merck$20K
- Theratechnologies Inc.$7K
- Gilead$4K
- Janssen Scientific Affairs, LLC$2K
- Johnson & Johnson$767
- plus $2K from 19 others
Across 1 payment — averaging $4500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$5K
What the payments were for
- Consulting fees$13,41522%
- Speaking & faculty fees$28,59047%
- Travel & lodging$7,53812%
- Food & beverage$11,35219%
- Education$3010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 217 | $26,385 |
| Merck | 79 | $19,781 |
| Theratechnologies Inc. | 58 | $7,044 |
| Gilead | 136 | $3,860 |
| Janssen Scientific Affairs, LLC | 1 | $1,560 |
| Johnson & Johnson(2 entities) | 52 | $767 |
| AbbVie(2 entities) | 34 | $710 |
| EMD Serono, Inc. | 11 | $178 |
| Janssen Products, LP | 3 | $175 |
| Napo Pharmaceuticals Inc | 9 | $150 |
| Novo Nordisk | 7 | $129 |
| Antares Pharma, Inc. | 5 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $99 |
| AstraZeneca | 3 | $41 |
| GSK | 2 | $34 |
| Pfizer | 2 | $31 |
| Lilly USA, LLC | 2 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Argon Medical Devices, Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,196 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 169 | $658,754 |
| CabenuvaCabotegravir/Rilpivirine | 48 | $243,031 |
| DovatoDolutegravir Sodium/Lamivudine | 70 | $197,649 |
| TrogarzoIbalizumab-Uiyk | 12 | $142,364 |
| DescovyEmtricitabine/Tenofov Alafenam | 64 | $142,077 |
| JulucaDolutegravir/Rilpivirine | 30 | $111,525 |
| PrezcobixDarunavir/Cobicistat | 34 | $93,852 |
| TivicayDolutegravir Sodium | 32 | $70,024 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 21 | $60,468 |
| OzempicSemaglutide | 56 | $58,940 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $52,598 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $48,022 |
| PifeltroDoravirine | 15 | $26,749 |
| MounjaroTirzepatide | 20 | $22,268 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $12,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $3,860 | $848,854245 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Juluca, Tivicay | $26,385 | $622,228180 claims |
| Theratechnologies Inc.Trogarzo | $7,044 | $142,36412 claims |
| Johnson & JohnsonPrezcobix | $767 | $93,85234 claims |
| Novo NordiskOzempic | $129 | $58,94056 claims |
| Janssen Products, LPSymtuza | $175 | $52,59812 claims |
| MerckPifeltro | $19,781 | $26,74915 claims |
| Lilly USA, LLCMounjaro | $27 | $22,26820 claims |
| GSKAnoro Ellipta | $34 | $12,52128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Jacksonville
- Pablo PellaJacksonville$124K
- Shalika KatugahaJacksonville$46K
- Om KapoorJacksonville$20K
- Ivan GuerreroJacksonville$20K
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.